MannKind (MNKD) to Announce Quarterly Earnings on Wednesday

MannKind (NASDAQ:MNKD) is expected to be issuing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.02) per share and revenue of $108.8040 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

MannKind (NASDAQ:MNKD) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.03). MannKind had a negative return on equity of 11.21% and a negative net margin of 6.63%.The firm had revenue of $90.17 million for the quarter, compared to analysts’ expectations of $105.38 million. During the same quarter last year, the firm posted $0.04 earnings per share. The firm’s revenue for the quarter was up 15.1% compared to the same quarter last year. On average, analysts expect MannKind to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MannKind Stock Performance

Shares of MNKD stock opened at $3.90 on Wednesday. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -55.63 and a beta of 1.09. MannKind has a 52-week low of $2.23 and a 52-week high of $6.51. The company has a 50-day simple moving average of $3.86 and a two-hundred day simple moving average of $3.86.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on MNKD shares. Wells Fargo & Company set a $11.00 target price on MannKind and gave the stock an “overweight” rating in a research note on Monday, June 1st. Mizuho decreased their price target on MannKind from $8.00 to $7.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of MannKind in a report on Wednesday, July 8th. Zacks Research cut MannKind from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 7th. Finally, Royal Bank Of Canada increased their target price on shares of MannKind from $3.50 to $4.75 and gave the company a “sector perform” rating in a research report on Thursday, May 7th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $8.97.

Insider Transactions at MannKind

In other MannKind news, Director Steven B. Binder sold 16,940 shares of MannKind stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $3.29, for a total transaction of $55,732.60. Following the completion of the transaction, the director owned 808,008 shares of the company’s stock, valued at $2,658,346.32. The trade was a 2.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On MannKind

A number of institutional investors and hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd boosted its position in shares of MannKind by 108.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,636 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 2,927 shares during the period. Lido Advisors LLC bought a new stake in MannKind during the 4th quarter worth approximately $63,000. Mercer Global Advisors Inc. ADV purchased a new stake in MannKind in the 4th quarter worth approximately $70,000. Freestone Grove Partners LP purchased a new stake in MannKind in the 4th quarter worth approximately $80,000. Finally, Ameriprise Financial Inc. grew its position in shares of MannKind by 45.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 17,055 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 5,300 shares in the last quarter. 49.55% of the stock is owned by hedge funds and other institutional investors.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).